| Baranda, Joaquina C |
NCT04169347: FOLFOXIRI Plus Panitumumab in Metastatic RAS Wild-type, Left-sided Colorectal Cancer |
|
|
| Active, not recruiting | 2 | 27 | US | Oxaliplatin, Irinotecan, Leucovorin, Panitumumab | Criterium, Inc., Amgen | Colorectal Cancer Metastatic | 12/24 | 01/25 | | |
NCT05584670 / 2022-001239-95: A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid Tumors |
|
|
| Recruiting | 1/2 | 285 | Europe, US, RoW | SAR445877, Cetuximab, Erbitux | Sanofi, Sanofi Aventis Recherche & Développement | Solid Tumor | 01/27 | 09/28 | | |
WEE1, NCT04768868: The Safety and Pharmacokinetics Preliminary Efficacy of IMP7068 in Patients With Advanced Solid Tumors |
|
|
| Recruiting | 1 | 350 | US, RoW | IMP7068 | Impact Therapeutics, Inc., Covance | Advanced Solid Tumors | 04/23 | 08/23 | | |
NCT04412616: ZZ06 in Adult Patients With Advanced EGFR Positive Solid Tumor Malignancies |
|
|
| Recruiting | 1 | 60 | US, RoW | ZZ06 | Changchun Intellicrown Pharmaceutical Co. LTD, Covance | Advanced EGFR Positive Solid Tumor | 12/23 | 04/24 | | |
| Khan, Qamar |
EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer |
|
|
| Recruiting | 3 | 6000 | Europe, Canada, Japan, US, RoW | Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane | Eli Lilly and Company | Breast Neoplasms | 10/27 | 03/32 | | |
NCT00921115: Anti-Hormone Therapy (With Anastrazole and Fulvestrant) Before Surgery to Treat Postmenopausal Women With Breast Cancer. |
|
|
| Completed | 2 | 42 | US | Fulvestrant, Faslodex, Anastrazole, Arimidex | University of Kansas Medical Center, AstraZeneca | Invasive Breast Cancer | 04/15 | 03/23 | | |
FELINE, NCT02712723: Letrozole Plus Ribociclib or Placebo as Neo-adjuvant Therapy in ER-positive, HER2-negative Early Breast Cancer |
|
|
| Active, not recruiting | 2 | 121 | US | Letrozole, Femara, CGS 20267, LTZ, Ribociclib, LEE011, LEE-011, Placebo | Qamar Khan, Novartis Pharmaceuticals | Breast Cancer | 08/18 | 04/23 | | |
NCT06374459: Zunsemetinib in Combination With Capecitabine in Patients With Hormone Receptor-Positive and HER2-Negative Metastatic Breast Cancer With Bone Metastasis |
|
|
| Recruiting | 1/2 | 152 | US | Zumsemetinib, ATI-450, Capecitabine, Zoledronic acid, Denosumab | Washington University School of Medicine, United States Department of Defense, Aclaris Therapeutics, Inc. | Hormone Receptor Positive HER-2 Negative Metastatic Breast Cancer | 05/32 | 05/32 | | |
NCT04606342: ATI-450 in Combination With Paclitaxel or Capecitabine in Patients With Hormone Receptor-positive and HER2 Negative Metastatic Breast Cancer With Bone Metastasis |
|
|
| Not yet recruiting | 1/2 | 150 | US | ATI-450, Paclitaxel, Capecitabine, Antiresorptive Agents | Washington University School of Medicine, Aclaris Therapeutics, Inc., United States Department of Defense | Breast Cancer, Cancer of Breast | 05/25 | 04/28 | | |
| Withdrawn | 1 | 36 | NA | ATI-2231 | Washington University School of Medicine, Aclaris Therapeutics, Inc. | Advanced Solid Tumor, Advanced Solid Tumor Malignancies | 06/25 | 06/25 | | |
| Hepler, Kerry |
| Recruiting | 2a | 108 | US | BP1001 in combination with Ventoclax plus decitabine, Liposomal Grb-2, L-Grb-2, BP1001 plus decitabine | Bio-Path Holdings, Inc. | Acute Myeloid Leukemia (AML) | 12/24 | 12/24 | | |
| Active, not recruiting | 2 | 18 | US | Niraparib Treatment | University of Kansas Medical Center, Tesaro, Inc. | Pancreatic Cancer | 04/23 | 02/25 | | |
NCT03488667: Perioperative mFOLFOX Plus Pembrolizumab in Gastroesophageal Junction (GEJ) and Stomach Adenocarcinoma |
|
|
| Active, not recruiting | 2 | 40 | US | Neoadjuvant Treatment - mFOLFOX6 & Pembrolizumab, Adjuvant Treatment - mFOLFOX & Pembrolizumab | University of Kansas Medical Center, Merck Sharp & Dohme LLC | Gastro Esophageal Junction Cancer, Stomach Cancer, Adenocarcinoma | 04/24 | 04/25 | | |
TESLA, NCT05638698: Tg01 Vaccine / Qs-21 Stimulon™ With Or Without Balstilimab As Maintenance Therapy Following Adjuvant Chemotherapy In Patients With Resected Pancreatic Cancer |
|
|
| Active, not recruiting | 2 | 24 | US | TG01 Vaccine, QS-21, Balstilimab | University of Kansas Medical Center, Targovax ASA | Pancreas Cancer | 12/24 | 12/25 | | |
| Navigation, KUCC |
HOTT, NCT05659381: Heated Intraperitoneal Chemotherapy Followed by Niraparib for Ovarian, Primary Peritoneal and Fallopian Tube Cancer |
|
|
| Recruiting | 3 | 230 | US | Cisplatin, Platinol AQ, No treatment | GOG Foundation, GlaxoSmithKline | Stage III Ovarian Cancer, Stage IV Ovarian Cancer, Stage III Primary Peritoneal Cancer, Stage IV Primary Peritoneal Cancer, Stage III Fallopian Tube Cancer, Stage IV Fallopian Tube Cancer | 08/29 | 08/34 | | |
NCT03762161: A Phase II Study of Lonsurf (TAS-102) in Metastatic Platinum and Checkpoint Inhibitor-resistant Bladder Cancer |
|
|
| Recruiting | 2 | 22 | US | TAS 102 | Rahul Parikh, Taiho Oncology, Inc. | Bladder Cancer | 07/23 | 01/24 | | |
TESLA, NCT05638698: Tg01 Vaccine / Qs-21 Stimulon™ With Or Without Balstilimab As Maintenance Therapy Following Adjuvant Chemotherapy In Patients With Resected Pancreatic Cancer |
|
|
| Active, not recruiting | 2 | 24 | US | TG01 Vaccine, QS-21, Balstilimab | University of Kansas Medical Center, Targovax ASA | Pancreas Cancer | 12/24 | 12/25 | | |
BDTX-1535-101, NCT05256290: Phase 1/2 Study of BDTX-1535 in Patients with Glioblastoma or Non-Small Cell Lung Cancer with EGFR Mutations |
|
|
| Recruiting | 1/2 | 200 | US | BDTX-1535 monotherapy | Black Diamond Therapeutics, Inc. | Non-Small Cell Lung Cancer, Advanced Non-Small Cell Squamous Lung Cancer, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Lung Cancer, NSCLC, Advanced Lung Carcinoma, Epidermal Growth Factor Receptor C797S, Epidermal Growth Factor Receptor G719X, EGF-R Positive Non-Small Cell Lung Cancer, EGFR-TKI Resistant Mutation | 07/25 | 06/26 | | |
